( Tokyo:4502, OTC-PINK:TKPYY )

News from Takeda Pharmaceutical Company Limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 01, 2017, 04:30 ET Meta-Analysis Using Real-World Data Evaluates Safety Profile of Entyvio® (vedolizumab) in Patients with Moderate to Severe Ulcerative Colitis or Crohn's Disease

New meta-analysis provides a comprehensive view of real-world data and furthers understanding of Entyvio as an important treatment option...


Oct 16, 2017, 08:00 ET New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve Patients

Takeda Pharmaceutical Company Limited (TSE: 4502), ("Takeda") today announced the presentation of data suggesting early symptomatic improvement in...


Sep 26, 2017, 09:00 ET Takeda Named To 2017 Working Mother "100 Best Companies" For Leadership In Family Benefits And Paid Leave

Working Mother magazine today recognized Takeda Pharmaceuticals as one of the 2017 Working Mother 100 Best Companies for its strong leadership in...


May 08, 2017, 10:30 ET New Real-World Analyses Support Effectiveness and Safety of Entyvio® (vedolizumab) for Ulcerative Colitis and Crohn's Disease

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced the presentation of eight real-world analyses supporting the...


Oct 17, 2016, 02:00 ET Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") is presenting data on the real-world effectiveness and safety of vedolizumab in...


Sep 28, 2016, 15:16 ET Additional Interim Data Supporting Long-Term Use of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease Published in Journal of Crohn's and Colitis

 Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced that two interim reports from the ongoing, open-label GEMINI long-term...


Sep 27, 2016, 08:15 ET Takeda Named To 2016 Working Mother "100 Best Companies" For Leadership In Creating Progressive Programs To Support Working Families

Working Mother magazine today recognized Takeda as one of the 2016 "Working Mother 100 Best Companies" for its outstanding leadership in creating...


Sep 16, 2016, 10:48 ET Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced that an exploratory analysis of the GEMINI 1 data, evaluating...


Aug 02, 2016, 02:00 ET Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease

Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV (Euronext Brussels: TIG) ("TiGenix") today announced that the 24-week...


Jul 05, 2016, 02:00 ET Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. Rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease

 Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV (Euronext Brussels: TIG) ("TiGenix") today announced that the...


Jun 11, 2016, 13:31 ET EXAMINE Trial Post-Hoc Analyses of Mortality Data Regarding Cardiovascular Safety of Alogliptin Presented at American Diabetes Association's 76th Scientific Sessions and Published in Diabetes Care

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") announced the publication of a post-hoc analysis from the global EXAMINE (EXamination...


Jun 08, 2016, 08:29 ET Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders

Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") today announced...


Jun 06, 2016, 09:38 ET Takeda to Present New Data at the American Diabetes Association's 76th Scientific Sessions

 Takeda Pharmaceuticals Company Limited [TSE: 4502], ("Takeda") will present eight abstracts at the American Diabetes Association's 76th...


May 23, 2016, 12:33 ET Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week (DDW) Annual Meeting

Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") today announced the oral presentations of two data analyses: one evaluating the...


Apr 28, 2016, 13:00 ET Takeda Expands Its Help At Hand Patient Assistance Program in U.S.; Reaches Even More Eligible Patients in the U.S.

Takeda today announced its U.S. Business Unit will expand its patient assistance program to make its prescription drugs available to more eligible...


Nov 13, 2015, 10:18 ET Takeda Receives Back-to-Back Recognition, Named a 2015 Top Chicago Workplace

 Takeda announced today that the Chicago Tribune named Takeda's Deerfield campus among Chicago's Top 100 Workplaces in 2015. This is the fourth...


Oct 27, 2014, 11:00 ET Trate los síntomas del reflujo gracias a la Food4GERD App

La enfermedad del reflujo gastroesofágico (GERD), a menudo conocida como ardor de estómago, es un problema importante para muchas...


Oct 20, 2014, 08:00 ET Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI) Extended-Release Tablets for Chronic Weight Management in Obese Adults

 Takeda Pharmaceutical Company Limited ("Takeda"), its wholly-owned subsidiary Takeda Pharmaceuticals U.S.A., Inc. and Orexigen®...


Aug 28, 2014, 12:09 ET Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the post-marketing commitment and submissions of data from...


Jul 10, 2014, 09:00 ET Takeda and Zinfandel Pharmaceuticals to Present Data at Upcoming Alzheimer's Association International Conference® Highlighting Innovative Approaches to Alzheimer's Disease Research and Development

 Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), will present data during...


May 20, 2014, 18:14 ET FDA Approves Takeda's Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the...


Mar 27, 2014, 08:00 ET Takeda Presents Additional Data from the EXAMINE Cardiovascular Safety Outcomes Trial at the American College of Cardiology's 63rd Annual Scientific Session

Takeda Pharmaceutical Company Limited (Takeda) will present sub-analyses from the global EXAMINE (EXamination of CArdiovascular OutcoMes:...


Dec 24, 2013, 10:57 ET Takeda Announces Extension of FDA PDUFA Action Date for Vedolizumab for Ulcerative Colitis

 Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that...


Dec 09, 2013, 20:09 ET FDA Advisory Committee Recommends Approval of Takeda's Investigational Biologic Vedolizumab

 Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a...


Sep 20, 2013, 09:00 ET Takeda Cares Day Raises $63,700

 Takeda, a top 15 global pharmaceutical company, will raise money for local organizations today when employees participate in their third...